ArticleTechnology in cancer research & treatment

Evaluation of RC48-ADC in Combination with PRaG Regimen: An Open-Label, Prospective, Multicentre Study Assessing Efficacy and Safety for Advanced Refractory HER2-Expressing Solid Tumors (PRaG3.0 Study Protocol).

Meiling Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.